Market Overview

UPDATE: Feltl and Company Reiterates NxStage Medical at Hold; Reduces 2012 Revenue Estimates

Related NXTM
xStage Receives FDA Clearance for Home Nocturnal Hemodialysis
Benzinga's Volume Movers

Feltl and Company reiterated its Hold rating and $15 price target on NxStage Medical (NASDAQ: NXTM) as it tweaked the revenue forecast for 2012 to reflect shift in shipment from the third quarter to the fourth.

Feltl and Company noted, "We are modestly adjusting our Home revenue model assumptions as it has become clearer the Home business is running below the company's $1.2 million to $1.6 million sequential growth rate target, and at this point we have no reason to believe a near term acceleration is likely. We now model $0.9 million and $1.0 million sequential growth for 3Q12 and 4Q12, equating to $64.3 million of Home revenue during the second half of 2012, down 1.3% from our previous estimates."

NxStage Medical closed at $13.25 on Thursday.

Latest Ratings for NXTM

DateFirmActionFromTo
Sep 2014Canaccord GenuityMaintainsBuy
Mar 2014Wells FargoDowngradesMarket PerformUnderperform
Jul 2013Lazard Capital MarketsDowngradesBuyNeutral

View More Analyst Ratings for NXTM
View the Latest Analyst Ratings

Posted-In: Feltl And CompanyAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (NXTM)

Around the Web, We're Loving...

Get Benzinga's Newsletters